Frederic Jean Zecri from 19 Bowker St, Brookline, MA 02445, age 52, Phone: (617)5660651

Resumes

Global Head Oncology And Immuno-Oncology Chemistry At Novartis Institutes

view source

Location:

Brookline, MA

Industry:

Pharmaceuticals

Work:

Novartis Institutes For Biomedical Research (Nibr)
Global Head Oncology and Immuno-Oncology Chemistry at Novartis Institutes
Novartis Institutes For Biomedical Research (Nibr) Dec 2016 - Oct 2018
Director Medicinal Chemistry
Novartis Institutes For Biomedical Research (Nibr) Oct 2018 - Oct 2018
Novartis Leading Scientist
Novartis Institutes For Biomedical Research (Nibr) Jun 2011 - Nov 2016
Group Leader
Novartis Institutes For Biomedical Research (Nibr) Nov 2009 - Jun 2011
Senior Research Investigator

Education:

Dyson School of Design Engineering 1998 - 2000
Doctorates, Doctor of Philosophy Imperial College London

Skills:

Drug Discovery
Medicinal Chemistry
Drug Development
Drug Design
Purification
Organic Synthesis
Organic Chemistry
Pharmaceutical Industry
Life Sciences
Lead Change
High Throughput Screening
Chemistry
Lc Ms
Hplc
Lifesciences
Oncology
Clinical Development

Languages:

French
English
German

Us Patents

Cyclic Bridgehead Ether Dgat1 Inhibitors
view source
US Patent:

20130289058, Oct 31, 2013
Filed:

Apr 26, 2013
Appl. No.:

13/871586
Inventors:

Sejal Patel - Lexington MA, US
Justin Mao - North Reading MA, US
Qian Lui - Malden MA, US
Rui Zheng - Chestnut Hill MA, US
Tyler Harrison - Somerville MA, US
Rohit Duvadie - Arlington MA, US
Xin Chen - Lexington MA, US
Frederic Zecri - Brookline MA, US
Jay Larrow - Cambridge MA, US
Xuchun Zheng - Changshu, CN
Yizong Zhou - Changshu, CN
Jiong Ye - Changshu, CN
Yiping Ding - Changshu, CN
Yu Gai - Changshu, CN
International Classification:

C07D 493/08
A61K 31/506
A61K 45/06
A61K 31/4245
A61K 31/422
A61K 31/4439
A61K 31/433
US Classification:

514275, 5462691, 514337, 5462687, 544331, 548138, 514363, 548143, 514364, 548236, 514374, 548234, 514377, 5462714
Abstract:

The invention relates to compounds of formula (I):useful for treating disorders mediated by acyl coA-diacylglycerol acyl transferase 1 (DGAT1), e.g. metabolic disorders. The invention also provides methods of treating such disorders, and compounds and compositions etc. for their treatment.

Dihydro-Benzo-Oxazine And Dihydro-Pyrido-Oxazine Derivatives
view source
US Patent:

20130165436, Jun 27, 2013
Filed:

Dec 20, 2012
Appl. No.:

13/721805
Inventors:

Novartis AG - Basel, CH
Sylvie CHAMOIN - Saint Louis, FR
Pascal FURET - Thann, FR
Klemens HOGENAUER - Oberwil, CH
Konstanze HURTH - Lorrach, DE
Christoph KALIS - Gundelfingen, DE
Karen KAMMERTOENS - Village-Neuf, FR
Ian LEWIS - Riehen, CH
Henrik MOEBITZ - Freiburg, DE
Alexander Baxter SMITH - Niffer, FR
Nicolas SOLDERMANN - Village-Neuf, FR
Romain WOLF - Schlierbach, FR
Frederic ZECRI - Brookline MA, US
Assignee:

NOVARTIS AG - Basel
International Classification:

A61K 31/538
C07D 413/14
US Classification:

5142305, 544105
Abstract:

The invention relates to dihydro-benzo-oxazine and dihydro-pyrido-oxazine compounds of the formula (I) and/or pharmaceutically acceptable salts and/or solvates thereof,wherein Y, V, W, U, Q, R, R, Rand Rare as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of the PI3K enzymes.

Lipids And Lipid Compositions For The Delivery Of Active Agents
view source
US Patent:

20210078936, Mar 18, 2021
Filed:

Nov 25, 2020
Appl. No.:

17/104294
Inventors:

- BASEL, CH
Delai CHEN - Cambridge MA, US
Gabriel GAMBER - Cambridge MA, US
Andrew GEALL - Cambridge MA, US
Kevin LOVE - Somerville MA, US
Thomas ZABAWA - Cambridge MA, US
Frederic ZECRI - Cambridge MA, US
International Classification:

C07C 229/12
C07C 229/38
C07D 205/04
C07D 265/30
C07D 207/12
C07D 207/16
C07D 211/22
C07D 295/088
C07D 211/46
C07D 211/60
C07D 211/62
C07D 295/15
C07C 271/20
C07C 219/04
A61K 47/18
A61K 9/127
A61K 9/51
A61K 31/7105
A61K 31/713
A61K 39/12
A61K 39/39
C07C 271/22
C07D 211/06
C07D 211/34
C07D 211/44
Abstract:

This invention provides for a compound of formula (I):or a pharmaceutically acceptable salt thereof, wherein R-R, L, n and p are defined herein. The compounds of formula (X) and pharmaceutically acceptable salts thereof are cationic lipids useful in the delivery of biologically active agents to cells and tissues.

Novel Fatty Acids And Their Use In Conjugation To Biomolecules
view source
US Patent:

20210000964, Jan 7, 2021
Filed:

Jun 1, 2020
Appl. No.:

16/889201
Inventors:

- Basel, CH
Avirup BOSE - Marlborough MA, US
Alexandra Marshall BRUCE - Cambridge MA, US
Alokesh DUTTAROY - Marlborough MA, US
Chikwendu IBEBUNJO - Newton MA, US
Aaron KANTER - Somerville MA, US
Louise Clare KIRMAN - Swampscott MA, US
Changgang LOU - Somerville MA, US
Aimee Richardson USERA - Winchester MA, US
Ken YAMADA - Brookline MA, US
Jun YUAN - Boston MA, US
Frederic ZECRI - Brookline MA, US
International Classification:

A61K 47/54
A61K 38/095
A61K 38/08
A61K 38/16
A61K 38/17
A61K 38/18
A61K 38/22
A61K 45/06
C07C 55/02
C07C 55/22
C07C 57/02
C07C 57/18
C07C 59/245
C12N 15/113
Abstract:

The invention provides a conjugate comprising a biomolecule linked to a fatty acid via a linker wherein the fatty acid has the following Formulae A1, A2 or A3:

Tetrahydro-Pyrido-Pyrimidine Derivatives
view source
US Patent:

20200392132, Dec 17, 2020
Filed:

Jun 30, 2020
Appl. No.:

16/916168
Inventors:

- Basel, CH
Paulo Fernandes Gomes Dos Santos - Basel, CH
Nadege Graveleau - Basel, CH
Christina Hebach - Basel, CH
Klemens Hoegenauer - Basel, CH
Gregory John Hollingworth - Horsham, GB
Alexander Baxter Smith - Basel, CH
Nicolas Soldermann - Basel, CH
Frank Stowasser - Basel, CH
Ross Sinclair Strang - Basel, CH
Nicola Tufilli - Basel, CH
Anette von Matt - Basel, CH
Romain Wolf - Basel, CH
Frederic Zecri - Cambridge MA, US
Assignee:

Novartis AG - Basel
International Classification:

C07D 471/04
A61K 31/519
A61K 31/5377
Abstract:

The invention relates to substituted tetrahydro-pyrido-pyrimidine derivatives of the formula (I),wherein Y, R, Rand m are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of the PI3K enzymes.

Novel 3' End Caps, 5' End Caps And Combinations Thereof For Therapeutic Rna
view source
US Patent:

20200190132, Jun 18, 2020
Filed:

Feb 26, 2020
Appl. No.:

16/802014
Inventors:

- Basel, CH
Scott Louis COHEN - Burlington MA, US
John Louis DIENER - Cambridge MA, US
Christian GAMPE - Watertown MA, US
James ROACHE - Cambridge MA, US
Amy WHITE - Somerville MA, US
Sarah Louise WILLIAMS - Livermore CA, US
Jun YUAN - Boston MA, US
Frederic ZECRI - Brookline MA, US
International Classification:

C07H 21/02
C07K 14/575
C07H 19/207
C07H 19/167
C07F 9/6561
Abstract:

The disclosure relates to nucleic acids that contain modifications at the 5′-end, 3′-end or 5′-end and 3′-ends, and compounds that can be used to make the modified nucleic acids are disclosed. The modified nucleic acids have improved expression, lower immunogenicity and improved stability compared to unmodified nucleic acids.

Lipids And Lipid Compositions For The Delivery Of Active Agents
view source
US Patent:

20190358170, Nov 28, 2019
Filed:

Aug 12, 2019
Appl. No.:

16/537934
Inventors:

- Basel, CH
Delai Chen - Cambridge MA, US
Gabriel Grant Gamber - Cambridge MA, US
Andrew Geall - Cambridge MA, US
Kevin Love - Somerville MA, US
Thomas Zabawa - Cambridge MA, US
Frederic Zecri - Cambridge MA, US
International Classification:

A61K 9/51
C12N 15/113
C12N 7/00
C07D 295/13
C07D 233/64
C07D 211/46
C07D 211/06
C07C 235/08
A61K 39/12
A61K 38/22
A61K 38/18
A61K 9/127
C07C 323/52
C07D 211/62
C07D 211/22
C07D 207/16
C07D 207/12
C07C 229/12
C07C 219/06
C07D 319/06
Abstract:

This invention provides for a compound of formula (I):or a pharmaceutically acceptable salt thereof, wherein R-R, n, p, Land Lare defined herein. The compounds of formula (I) and pharmaceutically acceptable salts thereof are cationic lipids useful in the delivery of biologically active agents to cells and tissues.

Tetrahydro-Pyrido-Pyrimidine Derivatives As Pi3Kdelta Inhibitors
view source
US Patent:

20190218217, Jul 18, 2019
Filed:

Mar 28, 2019
Appl. No.:

16/367525
Inventors:

- Basel, CH
Paulo Fernandes Gomes Dos Santos - Basel, CH
Nadege Graveleau - Hesingue, FR
Christina Hebach - Meunchenstein, CH
Klemens Hoegenauer - Oberwil, CH
Gregory John Hollingworth - Kent, GB
Alexander Baxter Smith - Niffer, FR
Nicolas Soldermann - Village-Neuf, FR
Frank Stowasser - Murg, DE
Ross Sinclair Strang - Hagenthal le Bas, FR
Nicola Tufilli - Moehlin, CH
Anette von Matt - Biel-Benken, CH
Romain Wolf - Schlierbach, FR
Frederic Zecri - Brookline MA, US
International Classification:

C07D 471/04
A61K 31/519
A61K 31/5377
Abstract:

The invention relates to substituted tetrahydro-pyrido-pyrimidine derivatives of the formula (I),wherein Y, R1, R2 and m are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of the PI3K enzymes.